Organizers: IRB Barcelona
Date: Friday 22 February, 12.00h
Place: Felix Serratosa Hall, Parc Científic de Barcelona, Spain
Host: Dr. Manuel Serrano (IRB Barcelona)
Abstract:
Organizers: IRB Barcelona
Date: Friday 22 February, 12.00h
Place: Felix Serratosa Hall, Parc Científic de Barcelona, Spain
Host: Dr. Manuel Serrano (IRB Barcelona)
Abstract:
Organizers: IRB Barcelona
Date: Tuesday 26 February, 10.00h
Place: Felix Serratosa Hall, Parc Científic de Barcelona, Spain
Host: Dr. Manuel Serrano (IRB Barcelona)
Aging and Metabolism Program Extraordinary Seminar
Gianmarco Di Mauro – Chromatin Structure and Function Laboratory
Title: “Functional analysis of the extraproteasomal ubiquitin receptor Dsk2/UBQLN in Drosophila and human cells”
Date and Time: Thursday, 28th February 2019. 11.00 h.
Room: Classroom number 61.102-61.104, first floor of the Doctor Aiguader building (Dr. Aiguader 80, Barcelona). - UPF Campus-Mar.
Organizers: IRB Barcelona
Date: Friday 1st March, 12.00h
Place: Auditorium, Parc Cientific de Barcelona
Plenary Seminar
Organizers: IRB Barcelona
Date: Friday, 8 March, 12:00h
Place: Felix Serratosa room
Host: Dr. Manuel Serrano, PhD - IRB Barcelona
Abstract
Organizer: IRB Barcelona & Fundació Esteve
Date: Monday and Tuesday, March 11-12, 09:00-18:00h
Place: Room Felix Serratosa, Parc Científic de Barcelona, Spain
Cancer is a multi-hit process involving mutations in oncogenes and tumour suppressors. It is altered by its environment including interactions between the tumour cells and the surrounding normal tissue, immune response, and whole body metabolism. As such, cancer studies benefit from whole animal platforms. The fruit fly Drosophila is an excellent, genetically-tractable system for modelling the development of cancer due to the conservation of cell signalling, proliferation, and survival networks between fly and human.
Stimulation of the immune system by blocking immunosuppressive checkpoints has shown spectacular impact in cancer therapy. There is increasing evidence that immunotherapy might elicit similar outcomes in non-oncological settings. This is the case, for example, of neurodegenerative disorders where blockade of immune checkpoints has beneficial effects. More generally, aging is associated with a progressive unbalance in the composition and activity of the different components of the immune system.